Bone Biologics (BBLG) Equity Ratio (2016 - 2017)
Historic Equity Ratio for Bone Biologics (BBLG) over the last 2 years, with Q3 2017 value amounting to 6.1.
- Bone Biologics' Equity Ratio rose 3239.19% to 6.1 in Q3 2017 from the same period last year, while for Sep 2017 it was 6.1, marking a year-over-year increase of 3239.19%. This contributed to the annual value of 11.93 for FY2016, which is N/A changed from last year.
- Per Bone Biologics' latest filing, its Equity Ratio stood at 6.1 for Q3 2017, which was up 3239.19% from 11.14 recorded in Q2 2017.
- In the past 5 years, Bone Biologics' Equity Ratio ranged from a high of 0.75 in Q1 2016 and a low of 11.93 during Q4 2016